These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 21831418)

  • 1. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
    Quoix E; Zalcman G; Oster JP; Westeel V; Pichon E; Lavolé A; Dauba J; Debieuvre D; Souquet PJ; Bigay-Game L; Dansin E; Poudenx M; Molinier O; Vaylet F; Moro-Sibilot D; Herman D; Bennouna J; Tredaniel J; Ducoloné A; Lebitasy MP; Baudrin L; Laporte S; Milleron B;
    Lancet; 2011 Sep; 378(9796):1079-88. PubMed ID: 21831418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
    Fiteni F; Anota A; Bonnetain F; Oster JP; Pichon E; Wislez M; Dauba J; Debieuvre D; Souquet PJ; Bigay-Game L; Molinier O; Dansin E; Poudenx M; Milleron B; Morin F; Zalcman G; Quoix E; Westeel V
    Eur Respir J; 2016 Sep; 48(3):861-72. PubMed ID: 27338193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
    Quoix E; Audigier-Valette C; Lavolé A; Molinier O; Westeel V; Barlesi F; Le Treut J; Pichon E; Dauba J; Otto J; Moreau L; Madelaine J; Dumont P; Margery J; Debieuvre D; Renault PA; Pujol JL; Langlais A; Morin F; Moro-Sibilot D; Souquet PJ
    Eur J Cancer; 2020 Oct; 138():193-201. PubMed ID: 32898792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].
    Quoix E; Ducoloné A; Mennecier B; Fraisse P
    Presse Med; 2011 Apr; 40(4 Pt 1):420-6. PubMed ID: 21388776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
    Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
    Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
    Duruisseaux M; Baudrin L; Quoix E; Wislez M; Moro-Sibilot D; Coëtmeur D; Monnet I; Mourlanette P; Morère JF; Soria JC; Westeel V; Morin F; Cadranel J
    J Thorac Oncol; 2012 Sep; 7(9):1423-31. PubMed ID: 22767177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
    Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
    Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
    Saito H; Nakagawa K; Takeda K; Iwamoto Y; Ando M; Maeda M; Katakami N; Nakano T; Kurata T; Fukuoka M
    Am J Clin Oncol; 2012 Feb; 35(1):58-63. PubMed ID: 21293243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
    Greco FA; Spigel DR; Kuzur ME; Shipley D; Gray JR; Thompson DS; Burris HA; Yardley DA; Pati A; Webb CD; Gandhi JG; Hainsworth JD
    Clin Lung Cancer; 2007 Sep; 8(8):483-7. PubMed ID: 17922972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
    Brunetto AT; Carden CP; Myerson J; Faria AL; Ashley S; Popat S; O'Brien ME
    J Thorac Oncol; 2010 Sep; 5(9):1397-403. PubMed ID: 20644495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
    Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
    Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
    Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
    Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
    Maemondo M; Inoue A; Sugawara S; Harada T; Minegishi Y; Usui K; Miwa K; Morikawa N; Kambe M; Ube K; Watanabe K; Ishimoto O; Sakakibara T; Gemma A; Nukiwa T
    Oncologist; 2014 Apr; 19(4):352-3. PubMed ID: 24682465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
    Ohe Y; Ohashi Y; Kubota K; Tamura T; Nakagawa K; Negoro S; Nishiwaki Y; Saijo N; Ariyoshi Y; Fukuoka M
    Ann Oncol; 2007 Feb; 18(2):317-23. PubMed ID: 17079694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.